Note: This data visualization was originally published in March 2017.
As of June 2019, an estimated 29 new nontraditional products1 with the potential to treat or prevent serious bacterial infections were in clinical development. Below is a snapshot of the current nontraditional products pipeline, based on publicly available information and informed by external experts. It is updated periodically, as products advance or are known to drop out of development. Because of periodic updates, endnote numbers may not be sequential. Please contact email@example.com with additions or updates.
Please contact firstname.lastname@example.org with additions or updates.
For definitions of drug development terms and nontraditional product types, visit https://www.pewtrusts.org/en/research-and-analysis/articles/2014/03/12/glossary-for-the-antibiotic-pipeline.
Note: The following drugs have been removed from the pipeline. Removed candidates will be included in future updates if development resumes:
Because the conventional antibiotics pipeline remains so thin, finding new approaches is critical